Bardoxolone, a Nrf2 activator, was found to raise estimated glomerular filtration rate during a 3-month follow-up according to a subanalysis of ADPKD patients in a clinical study of chronic kidney disease.132. This evidence concerns the gene NFE2L2 and autosomal dominant polycystic kidney disease.